

Primary Endpoint: Overall Success at Day 14

(Mycological eradication and resolution of systemic signs attributable to candidemia and/or invasive candidiasis.)

The STRIVE study was not powered for inferential statistics. The number and percentage of subjects with an overall success (mycological eradication/presumed eradication and resolution of systemic signs of candidemia and/or IC that were present at baseline), failure, and indeterminate response at Day 14 in the mITT population were presented. Exact 2-sided 95% CIs for the point estimates of overall success in each treatment group were determined using the Clopper-Pearson method.

Treatment Arm 1: Rezafungin Group 1

Treatment Arm 2: Rezafungin Group 2

Treatment Arm 3: Caspofungin IV

Type of Statistical Test	Method of Estimation		Confidence Interval Lower Limit	Confidence Interval Upper limit
	Estimation parameter	Estimated value		
Descriptive	Percentage	Arm 1 = 60.5% Arm 2 = 76.1% Arm 3 = 67.2%	Arm 1 = 48.6 Arm 2 = 61.2 Arm 3 = 54.0	Arm 1 = 71.6 Arm 2 = 87.4 Arm 3 = 78.7